Difference between revisions of "Combining-Lamotrigine-Carbamazepine"
From Psychiatrienet
| Line 8: | Line 8: | ||
* Start carbamazepine with a daily dose of 200 mg and increase dose based serum concentration if necessary. Check lamotrigines effect after 2 weeks of therapy and adapt dose if necessary. <ref name=”medicatiebewaking”> Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002. </ref> | * Start carbamazepine with a daily dose of 200 mg and increase dose based serum concentration if necessary. Check lamotrigines effect after 2 weeks of therapy and adapt dose if necessary. <ref name=”medicatiebewaking”> Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002. </ref> | ||
| cave = | | cave = | ||
| − | * Abrupt stop of carbamazepine can cause serious lamotrigine rash as lamotrigine levels increase. <ref | + | * Abrupt stop of carbamazepine can cause serious lamotrigine rash as lamotrigine levels increase. <ref> {{Pubmed|12648898|Koch HJ et al. Clinically relevant reduction of lamotrigine concentrations by carbamazepine. J Clin Psychiatry 2005;66:400-1}}</ref> |
}} | }} | ||
Revision as of 13:32, 4 March 2010
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
Adding Carbamazepine to Lamotrigine.
General information- Lamotrigine is principally metabolised by UDP-glucuronosyltransferases.
- Carbamazepine is principally metabolized by CYP3A4, and is a potent inducer of CYP1A2, CYP2C9, CYP3A4 and UDP-glucuronosyltransferases.
- Lamoptrigine is principally metabolised by UDP-glucuronosyltransferases.
- Carbamazepine is principally metabolized by CYP3A4 (also CYP2C8), but is also a potent inducer of CYP1A2, CYP3A4 and UDP-glucuronosyltransferases.
Start Carbamazepine- Start carbamazepine with a daily dose of 200 mg and increase dose based serum concentration if necessary. Check lamotrigines effect after 2 weeks of therapy and adapt dose if necessary. [6]
Cave- Abrupt stop of carbamazepine can cause serious lamotrigine rash as lamotrigine levels increase. [7]
- ↑ 1.0 1.1 Farmacotherapeutisch Kompas; Toxicologie (dutch)
- ↑ 2.0 2.1 Farmacotherapeutisch Kompas - lamotrigine (dutch)
Cite error: Invalid
<ref>tag; name "ftk" defined multiple times with different content - ↑ Drugs.com lamotrigine
- ↑ WHO Collaborating Centre for Drug Statistics Methodology ATC=N03AF01
- ↑ KNMP; Informatorium Medicamentorum 2023; Monografie "carbamazepine" (Dutch)
- ↑ Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002.
- ↑ Koch HJ et al. Clinically relevant reduction of lamotrigine concentrations by carbamazepine. J Clin Psychiatry 2005;66:400-1
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
